Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for The STOP-NIDDM
Trial Research Group.
The STOP-NIDDM trial was one of several recent studies pointing to the importance of postprandial glucose values.
In a subanalysis of the STOP-NIDDM trial, acarbose slowed the progression of intimal-medial thickness in subjects with IGT, the first placebo-controlled, prospective study to show that counterbalancing of postprandial hyperglycemia may be vasoprotective (Stroke 2004;35:1073-8).
was one of several recent studies pointing to the importance of postprandial glucose values, which have until recently received less attention than fasting glucose.
was an international randomized trial in which 1,368 patients with impaired glucose tolerance were randomized to acarbose--an alpha-glucosidase inhibitor that delays glucose absorption--or placebo.
Zeymer focused on a secondary end point of the STOP-NIDDM
(Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) trial.
Markolf Hanefeld of Dresden (Germany) University of Technology, separately presented another STOP-NIDDM
secondary analysis; this one aimed at picking out subgroups of patients with IGT in whom acarbose was particularly beneficial.